Evaluating treatment effect modifiers using data from randomized two-sequence, two-period crossover clinical trials: application to a diabetes study
Journal of the Royal Statistical Society Series C: Applied Statistics · 16.06.2025 · 74 (3) · 659-674
DOI: 10.1093/jrsssc/qlae072 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of the Royal Statistical Society Series C: Applied Statistics, online erschienen am 06.02.2025. Verfasst von Ryo Emoto und 5 weiteren Autor:innen. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Grant-in-Aid for Scientific Research, JST-CREST, Ministry of Education, Culture, Sports, Science, and Technology of Japan.
Themen: Diabetes mellitus
Abstract (Originalsprache)
Type 2 diabetes is known as a heterogeneous disease with diverse pathophysiology. The identification of treatment effect modifiers for personalized medicine, however, has been difficult in basic research due to complex biological mechanisms related to various genetic and nongenetic factors, and in clinical research due to confounding bias and limited sample sizes. In this paper, we focus on a two-sequence, two-period crossover (CO) clinical trial of type 2 diabetes with baseline markers as a new strategy for analyzing treatment effect modification that allows confounding elimination and efficiency enhancement by within-patient treatment comparison. We provide a framework for statistical analysis of treatment effect modification and develop methods for testing for treatment effect modification and estimating individualized predictors of treatment differences in the CO trial with limited sample size. Numerical assessments showed that the efficiency of the proposed CO analysis was substantially higher than the standard analysis based on parallel-group comparison in these analyses. Application to the diabetes trial showed that markers based on gene expression in peripheral blood cells before pharmacological treatment significantly modified the effect of the treatment on the response and that marker-based predictors produced two subgroups of patients for whom different treatments should be recommended.
Förderung
- Grant-in-Aid for Scientific Research
- JST-CREST
- Ministry of Education, Culture, Sports, Science, and Technology of Japan
Zitieren
APA
Emoto, R., Igeta, M., Matsui, K., Ishii, K., Takamura, T., & Matsui, S. (2025). Evaluating treatment effect modifiers using data from randomized two-sequence, two-period crossover clinical trials: application to a diabetes study. Journal of the Royal Statistical Society Series C: Applied Statistics, 74(3), 659-674. https://doi.org/10.1093/jrsssc/qlae072
Vancouver
Emoto R, Igeta M, Matsui K, Ishii K, Takamura T, Matsui S. Evaluating treatment effect modifiers using data from randomized two-sequence, two-period crossover clinical trials: application to a diabetes study. Journal of the Royal Statistical Society Series C: Applied Statistics. 2025;74(3):659-674. doi:10.1093/jrsssc/qlae072
BibTeX
@article{Emoto2025,
author = {Emoto, Ryo and Igeta, Masataka and Matsui, Kota and Ishii, Kiyoaki and Takamura, Toshinari and Matsui, Shigeyuki},
title = {Evaluating treatment effect modifiers using data from randomized two-sequence, two-period crossover clinical trials: application to a diabetes study},
journal = {Journal of the Royal Statistical Society Series C: Applied Statistics},
year = {2025},
volume = {74},
number = {3},
pages = {659--674},
doi = {10.1093/jrsssc/qlae072}
}
EUVIMED